Member Info for CHELSEA7

Samantha Paston..........................

https://www.bloomberg.com/profile/person/20928454

"""About Scancell Holdings PLC
Scancell Holdings PLC develops vaccines. The Company uses a human monoclonal antibody to target cells that stimulate immune system response. Scancell's vaccine can be customized against a specific disease."""

Following on from that article about Avidamab, many of us wondered why she had left Immunacore to join Scancell......................

"""Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab enhanced cell killing platform has broad partnering potential," said chief executive, Dr Cliff Holloway."""

Well it is a very short period of time since she left Immunacore to join Scancell, and we can see pretty clearly what she was working on there. Perhaps it was simply that Immunacore weren"t driving forward on this project, and it seems Lindy pulled off quite a coup getting her onboard here. Either way it seems it was a tremendous addition to our crew, and lets hope in another short period of time we can announce a commercial deal on this platform. I wonder what else Samanthe brought with her??

Here"s to a more interesting week here........... night guys

Scancell
Scancell’s breakthrough is called AvidiMab, which works with monoclonal antibodies that already form the basis of some very effective targeted cancer treatments.

The mAbs being developed by the AIM-listed drug developer are different, however, to the run of the mill antibody.

That’s because they target tumour-associated glycans that are associated with malignancies. The ability to hone in on these so-called TaGs is enhanced with the use of AvidiMab.

Scancell has produced a pipeline of these next-generation antibodies for use in the collaboration process.

“Our first collaboration and evaluation agreement with one of the major players in the antibody development field is a significant achievement in such a short period of time and we believe our novel AvidiMab enhanced cell killing platform has broad partnering potential," said chief executive, Dr Cliff Holloway."""

Anybody know who the major players might be?

Afternoon crumbs, yeah I saw they were in the highest daily risers list last week.

That kind of deal would suit us very nicely.

Dr Cliff Holloway, Chief Executive Officer, Scancell, said:



"We are delighted to welcome all six experienced clinicians to our Clinical Advisory Board and the creation of this Board is part of our wider strategy to fully develop and deliver the full potential of the Moditope platform across multiple tumour types. The initial focus of the Board will be to inform the clinical strategy for the planned Modi-1 clinical trial and to ensure the best possible outcome in several solid tumour indications, including ovarian cancer, head and neck cancer, and triple negative breast cancer. Significant progress has been made towards completing the GMP manufacture of the Modi-1 product and the preclinical testing required prior to the anticipated start of the trial early in 2020."



Chair of the Clinical Advisory Board, Professor Robert Coleman said:



"I am pleased to be working alongside Christian, Poulam, Iain, David and Stephen, who collectively have long, established track records in scientific and clinical research in oncology. I am looking forward to chairing the Clinical Advisory Board and working closely with my Board colleagues and the Scancell team to realise the full potential of Scancell's Moditope immunotherapy platform through future clinical development."

Some tremendous advisors, and we are going for it, they have my trust ans support. ATB

Scancell Establishes Clinical Advisory Board and Provides Update on Modi-1 Progress



Appoints six world class clinical oncologists to guide the Moditope clinical development strategy



Modi-1 manufacturing and toxicity testing underway to support anticipated start of Phase 1/2 study in

Q1 2020



Scancell Holdings plc, the developer of novel immunotherapies for the treatment of cancer, today announces that it has appointed six world-leading clinicians to establish its Clinical Advisory Board ("CAB"). The Board will be chaired by Professor Robert Coleman and will provide strategic guidance and support as the Company prepares for its lead Moditope candidate, Modi-1, to enter the clinic in Q1 2020 in multiple tumour types, including head and neck, breast and ovarian cancer.



The CAB comprises: Professor Robert Coleman, Emeritus Professor of Medical Oncology at Weston Park Hospital and the University of Sheffield; Professor Christian Ottensmeier, Professor of Experimental Cancer Medicine at the University of Southampton; Professor Poulam Patel, Professor of Clinical Oncology at the University of Nottingham and Honorary Consultant Medical Oncologist at the Nottingham University Hospitals NHS Trust; Professor Iain McNeish, Professor of Oncology and Head of the Division of Cancer within the Department of Surgery and Cancer, Imperial College London; Professor David Miles, Lead Clinician for breast cancer at Mount Vernon Cancer Centre; and Professor Stephen Chan, Director of Clinical Trials in Breast Cancer and Gynaecological Cancer at Nottingham University Hospital.



The Company also provides an update on progress towards initiating the Modi-1 Phase 1/2 clinical trial.



· Good Manufacturing Practice (GMP) synthesis of the bulk Modi-1 peptide conjugates is underway at the PolyPeptide Group's facilities in The Netherlands.



· The Company signed an agreement at the end of April 2019 with AMRI (Glasgow, UK), a global contract and manufacturing organisation, to formulate, manufacture and package the Modi-1 GMP final product for clinical testing.



· The preclinical toxicity testing programme required prior to the start of the clinical trial commenced in April 2019 and is anticipated to be completed during H2 2019.



Scancell's Moditope platform acts by stimulating the production of CD4 T cells using citrullinated tumour-associated peptide epitopes. This technology overcomes the immune suppression induced by tumours themselves, allowing activated T cells to seek out and kill tumour cells that would otherwise be hidden from the immune system. Previous pre-clinical data demonstrated that conjugation of the Modi-1 peptides to Amplivant enhances anti-tumour immune responses 10-100 fold and resulted in highly efficient tumour eradication, including protection against tumour recurrence.





"We are delighted to welcome all six experienced clinicians to our Clinical

Fills me with a lot of confidence too, in the organisation behind the MOD1 trial to appeal to individual parties specific needs. Well organised, to ensure maximum exposure to any interested parties.

Worth a read.................again.....................

https://www.lse.co.uk/rns/SCLP/scancell-hlds-clinical-advisory-board-and-update-on-modi-1-zse66sznj4eoozf.html

Seems so odd seeing this BB so quiet as it is now. It really is a case of sitting back and waiting for news. Think we all know the kind of news we are hoping for, but I haven"t ruled out the unexpected.

One thing I have asked many times is how are we funding the MOD1 trial? In the last few months preceeding the Vulpes deal a few of us mentioned the certainty in which Scancell were talking about forthcoming plans. It was as if they knew very well about the impending Vulpes deal, which in reaqlity paid for a years expenditure in making the wheels turn without another fund raise. I liken now to then, in as much as I do believe we know of another deal impending which will take us through the MOD1 trial at least. That in itself answers my question IMHO, just really hoping we get good news about the first six patiens being enrolled and even better that dosing has began.

Feeling more confident that the U.S.A arm will be reignited with an IND submission in the not too distant future, perhaps anothr couple of additional sites in the U.K. One thing I don"t agree with is how essential that is to the first six patients. It is not just in Nottingham theat we are enrolling, in fact Nottingham is strategically placed near enough in the middle of the U.K. so is enrolling six patients that difficult??

Ray I agree with your views about two differing types of Moditope trials, just have reasonable doubts about hitting the end H2 2020 proposed deadline, but I do think that any commercial deal will go a long way to funding the MOD1 trial.

One thing that has surprised me is semmingly at this stage a partner for Moditope trials has not emerged, or is that simply that Scancell are that sure of funding and are fully prepared to gather data before any such deals will be considered to ensure the best value for Company and shareholders alike. The emphasis from the company is consistantly about gathering data, and we are going alone. Talk of a BioNTech deal or anything from the 3rd platform will ensure that and I am more than happy this has been considered fully by Vulpes before we enter the market for any funding at this M/Cap level, circa £30m, which for 2 trials and waiting for news from CRUK for the SCIB2 Trial, and the value of the 3rd platform seems so undervalued. So we are back to patience, and I do feel the vibe from the AGM was we have a good stratagy and I wasn"t expecting news so soon after the event. Perhaps now and between Xmas we can hope realistacly for news that we all want.

Night you guys,

Well BioNTech must have needed that money for now, otherwise why not delay the IPO like ADC did??

And here I go spectulating on speculation, lol

Buys 54k.............2 Trades 30k at 6.6 and 24k at 6.7

Sells 76k..............1 Trade at 6.5p

Trades on NEX....................MMs take 11k at 6.5p

On the positive side CH has always said he hopes the relationship will bear (more?) fruit when the collaboration ends.

sorry bout that}.......that will have to be shelved for now. Lets hope that does not apply to us.

The only reason I said that was because the original plans were to raise substantially more in the IPO...............considerably more than the $150m they raised and perhaps not seen as a "windfall" as it might have been. Somewhere there has to be budget cuts on spending and we just don"t know where we stand as far as a deal goes.

Worth reading this article in Fierce Biotech..............................

"""BioNTech is also looking to the IPO to help fund some of its collaborations and get more assets into the clinic. The early-stage assets expected to benefit from the funding include candidates based on BioNTech’s research into CAR-Ts, T-cell receptors and mRNA-encoded antibodies and cytokines.

The breadth of the R&D strategy reflects the fact that the anticipated $100 million IPO haul will make up a fraction of BioNTech’s total spending power.

BioNTech is yet to say how many shares it will sell and at what price. But the penciled in total IPO haul of $100 million is far below the $800 million BioNTech was reportedly aiming to raise earlier this year. Since then, BioNTech has raised another private round, pulling in a $325 million series B to add to the $270 million series A it put together last year.

Those megarounds left BioNTech with $533 million in the bank. The figure would be higher still but an almost $90 million investment from a Hong Kong-based backer has been “indefinitely delayed.”

“BioNTech management believes the payment may have been delayed in part due to ongoing geopolitical disruptions in Hong Kong and the ongoing trade dispute between the U.S. and China,” the company wrote in its IPO filing. BioNTech expected to receive the money last month.

If the investor still hasn’t paid up by the time of the public offering, BioNTech plans to demand the return of the shares. BioNTech said that scenario could force it “to raise additional funds sooner than [it] would have anticipated.”

As I tried to say if BioNTech need our technology you would have thought they have considerable funds to purchase it, but I am equally sure there are some deals BioNT

30,303 on NEX

Ruck,

Well after listening to the AGM and a few comments by those present, it didn"t sound as if news was due imminantly, whatever that means, and yes 6/13 weeks sounded reasonable then, as it does now, one month later. Lets hope it is 6, lol.

Got no view really on BioNTech, only they know what was budgeted for, and if Scancell ranks high as a priority a deal if there is one will happen.

Just 14 trades and a "1" trade in a very underwhelming week. I agree with Ruck from yesterday will just be happy to hear the six patients have been enrolled and dosed for now. Not even speculating about the IND or BioNTech for now, just seems like we get to the point where we speculate over speculation, after 8 years here not going there, and just hoping one day soon we get news on any front that is good.

So, pleased this week is coming to an end, MMs just taking 11k at 6.5p at the close yesterday and that is with 4 MMs on the bid. Have a good day.

Thanks Bermuda, wow that is some sum, never imagined that cost was so high, and of course reimbursement for Keytruda is a big issue too.

So the IND according to CH is still very much part of the plan, which was the reason I wanted to see that clarrified, I think a few people have there wires crossed there, not ashmed to admit I do too.

Just reminding myself about the benefits of ODD............

""What are the benefits of orphan drug status?
The purpose of the designation was to create financial incentives for companies to develop new drugs and biologics for rare diseases. These incentives include a partial tax credit for clinical trial expenditures, waived user fees, and eligibility for 7 years of marketing exclusivity [1].19 Jun 2017""

What fees are the waived user fees that they mention??

Night guys.

Just 4 MMs on 6.5 now, taking just 10k at 6.5p

Bermuda, thanks for the reminder about 30 days

Ruck,

Understand that. I find it all very unclear TBH.

2 Sells over on NEX, one for 38k, the other 30k at 6.51

Sorry with Astra Zeneca